| Detailed information |
|---|
| CancerLivER ID | 2535 |
| Biomarker | ADAR, PSMD4, D9SVA, CCT3, GBAP, RDBP, CSRP2, ILR7 |
| Biomarker Name/Symbol (given in Publication) | ADAR, PSMD4, D9SVA, CCT3, GBAP, RDBP, CSRP2, ILR7 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | This signature is likely to be associated with dedifferentiation of HCC and validated on independent dataset |
| Experimental Condition | Moderately differentiated tumor (MD) v/s Well-differentiated tumor (WD) |
| Cancer type | Hepatocellular carcinoma |
| Regulation | ILR-7 is Downregulated while others are Upregulated in |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 12079511 |
| Type of Biomarker | Prognostic |
| Pathway | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways, Beta-Adrenergic Signaling and Metabolism of proteins,Cargo trafficking to the periciliary membrane and Cell cycle_Role of APC in cell cycle regulation, Immune response IL-23 signaling pathway and ATF-2 transcription factor network. |
| Cohort | Training dataset has 20 HCC patients: 7 chronic hepatitis, 13 with liver cirrhosis; 3 patients had multicentric nodules and one patient had NIN. Serologically, 6 patients with hepatitis B surface antigen positive, and 14 patients were hepatitis C virus positive; 24 tumors and corresponding noncancer |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Moderately differentiated tumor (MD) v/s Well-differentiated tumor (WD) |
| Year of Publication | 2002 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |